



# FallTech Conference 2017



**Monday, November 6, 2017**

**USP Workshop** (separate registration)

7:00 a.m. – 5:30 p.m.	<b>2017 Fall Technical Conference Registration</b> – Grand Ballroom Foyer
8:30 a.m. – 8:45 a.m.	<b>Welcome and Introduction</b> – Salon F-H <b>Robert Femia, PhD</b> Senior Vice President, Science-Chemical Medicines, USP
8:45 a.m. – 9:30 a.m.	<b>Analytical Procedure Lifecycle and Statistics: Applied to Analytical Procedures/General Chapters</b> <b>Horacio Pappa, PhD, CQE</b> Director, Compendial Science-General Chapters, USP
9:30 a.m. – 10:15 a.m.	<b>Elemental Impurities</b> <b>Horacio Pappa, PhD, CQE</b> Director, Compendial Science-General Chapters, USP
10:15 a.m. – 10:30 a.m.	<b>Networking Refreshment Break</b> – Grand Ballroom Foyer
10:30 a.m. – 11:15 a.m.	<b>Research and Innovation Activities</b> <b>Mike Ambrose, PhD</b> Director, Research & Innovation, USP
11:15 a.m. – 11:30 a.m.	<b>Closing Remarks</b> <b>Nelufar Mohajeri, MA, MPhil</b> Senior Director, Global Stakeholder Engagement, USP
11:30 a.m.	<b>Workshop Concludes</b>

**Monday, November 6, 2017**

**2017 AAM Fall Technical Conference - Day 1**

- 7:00 a.m. – 5:00 p.m.                      **2017 Fall Technical Conference Registration** – Grand Ballroom Foyer
- 11:30 a.m. – 1:00 p.m.                      **Networking Welcome Lunch** – Salon A-C
- 1:00 p.m. – 1:15 p.m.                      **Welcome and Introductions** – Salon D-E  
**David Gaugh, RPh**  
Senior Vice President, Sciences & Regulatory Affairs, AAM
- 1:15 p.m. – 1:45 p.m.                      **State of the Industry Address**  
**Chester “Chip” Davis, Jr., JD**  
President & CEO, AAM
- 1:45 p.m. – 2:30 p.m.                      **State of OGD Address**  
**Kathleen Uhl, MD**  
Director, Office of Generic Drugs (OGD), FDA
- 2:30 p.m. – 3:00 p.m.                      **Networking Refreshment Break** – Grand Ballroom Foyer
- 3:00 p.m. – 3:30 p.m.                      **FDA Commissioner Keynote Address**  
**Scott Gottlieb, MD**  
Commissioner, FDA
- 3:30 p.m. – 4:00 p.m.                      **State of OPQ Address**  
**Giuseppe Randazzo, MS**  
Director, Office of Program and Regulatory Operations (OPRO)  
Office of Pharmaceutical Quality (OPQ), FDA
- 4:00 p.m. – 4:30 p.m.                      **State of ORA Address**  
**Ellen Morrison**  
Assistant Commissioner, Medical Products and Tobacco Operations  
Office of Regulatory Affairs (ORA), FDA
- 4:30 pm – 5:30 pm                      **International Harmonization – IGBA Perspective**  
Moderator: **David, Gaugh, RPh**  
Senior Vice President, Sciences & Regulatory Affairs, AAM  
**Nicholas Cappuccino, Jr., PhD**  
Vice-President, Head of Quality and Scientific Affairs  
Dr. Reddy’s Laboratories, Inc.  
Chair, Science Committee IGBA  
**Sergio Napolitano, LLM**  
Legal and External Relations Director, Medicines for Europe
- 5:30 p.m. – 7:00 p.m.                      **Networking Welcome Reception** – Grand Ballroom Foyer

# Tuesday, November 7, 2017

## 2017 AAM Fall Technical Conference - Day 2

7:00 a.m. – 8:00 a.m.

**Networking Breakfast** – Salon A-C

8:00 a.m. – 9:00 a.m.

### Rising Drug Prices: Opportunities for Generics

Moderator: **Craig Burton**

Vice President, Policy, AAM

**Alex Brill**

CEO and Founder, Matrix Global Advisors, LLC

**Allan Coukell**

Senior Director, Health Programs, The Pew Charitable Trusts

**Matthew Eyles**

Senior Executive Vice President and Chief Operating Officer, AHIP

9:00 a.m. – 10:00 a.m.

### GDUFA II Pre – ANDA Program

Moderator: **Kiran Krishnan, PhD**

Senior Vice President, Global Regulatory Affairs, Apotex Corp.

**Robert Lionberger, PhD**

Director, Office of Research Standards (ORS), OGD, FDA

**Kris Andre, MS** (panelist)

Associate Director, Regulatory Affairs, ORS, OGD, FDA

**Michele Crawley, MS, RAC** (panelist)

Director, Regulatory Affairs, Cipla USA, Inc.

10:00 a.m. – 10:30 a.m.

**Networking Refreshment Break** – Grand Ballroom Foyer

10:30 a.m. – 12:00 p.m.

### Office of Generic Drugs GDUFA II Review Program Enhancements (Part I)

Moderator: **Scott Tomsky, MS, BS**

Vice President, Regulatory Affairs, Generics North America,  
Teva Pharmaceuticals

**CDR Kwadwo (Kojo) Awuah, PharmD, RAC**

Team Leader, Division of Filing Review

Office of Regulatory Operations (ORO), OGD, FDA

**LT Nicholas Daniel, PharmD, BCPS**

Regulatory Project Manager, DPM, ORO, OGD, FDA

**Michael Folkendt, MS**

Associate Director for Regulatory Affairs, OPRO, OPQ, FDA

**Tiffany Houser, PharmD**

Regulatory Project Manager

Division of Project Management (DPM), ORO, OGD, FDA

**LCDR Andrew Kim, PharmD**

Supervisory Project Manager, DPM, ORO, OGD, FDA

**Heidi Lee, PharmD**

Project Manager, Immediate Office (IO), ORO, OGD, FDA

**CDR Vincent Sansone, PharmD, CPH**

Deputy Director (Acting), ORO, OGD, FDA

**Priya Shah, PharmD**

Project Manager, IO, ORO, OGD, FDA

**Edward Sherwood, BA**

Director, ORO, OGD, FDA

12:00 p.m. – 1:30 p.m.

**Fall Technical Conference Luncheon** – Salon A-C/ WhiteOak

1:30 p.m. – 3:30 p.m.

**Office of Generic Drugs GDUFA II Review Program Enhancements (Part II)**

**Moderator: Scott Tomsky, MS, BS**

Vice President, Regulatory Affairs, Generics North America  
Teva Pharmaceuticals

**CDR Kwadwo (Kojo) Awuah, PharmD, RAC**

Team Leader, Division of Filing Review  
Office of Regulatory Operations (ORO), OGD, FDA

**LT Nicholas Daniel, PharmD, BCPS**

Regulatory Project Manager, DPM, ORO, OGD, FDA

**Michael Folkendt, MS**

Associate Director for Regulatory Affairs, OPRO, OPQ, FDA

**Tiffany Houser, PharmD**

Regulatory Project Manager

Division of Project Management (DPM), ORO, OGD, FDA

**LCDR Andrew Kim, PharmD**

Supervisory Project Manager, DPM, ORO, OGD, FDA

**Heidi Lee, PharmD**

Project Manager, Immediate Office (IO), ORO, OGD, FDA

**CDR Vincent Sansone, PharmD, CPH**

Deputy Director (Acting), ORO, OGD, FDA

**Priya Shah, PharmD**

Project Manager, IO, ORO, OGD, FDA

**Edward Sherwood, BA**


Director, ORO, OGD, FDA

3:30 p.m. – 4:00 p.m.

**Networking Refreshment Break** – Grand Ballroom Foyer

4:00 p.m. – 6:00 p.m.

**Expo Session** – Salon A-C and Foyer C



**FDA Booths:**

- Office of Management
- Drug Shortage Team
- Office of Regulatory Affairs
- Office of Strategic Programs - Office of Business Informatics

**Industry Booths:**

- Association for Accessible Medicines
- Pragmatic QbD for Generic Drug Development
- Operating Under GDUFA II
- From Bench to Bedside: A Sponsor's Perspective of the Journey of a Generic Drug
- Benefits of Harmonized Change Management
- Industry Timeline for Responses: CRLs, DRLs, IRs
- Quality ANDA Submission and Greater Transparency from FDA re Forfeiture Decisions

## **Expo Participants:**

**Erin Archer, JD**, Senior Manager, State Government Affairs, AAM

**Shawn Britton**, Product Manager, Lupin Pharmaceuticals, Inc.

**Kamilah Blackton**, Writer-Editor, Office of Communications and Project Management, ORA, FDA

**CAPT Tessa Brown, DHSc, MPH, RN**, Deputy Director, Division of Data Management Services and Solutions (DDMSS), FDA

**Germain Bryant, MA**, Management Analyst, Facilities Team, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

**Ethan Chen, PMP, MSE, MBA**, Director (Acting), DDMSS, FDA

**CAPT Christine Bina, RPh, MPH**, Team Leader, Drug Storage Staff, FDA

**Alonza Cruse**, Director, Office of Pharmaceutical Quality Operations, ORA, FDA

**Amy Byrom**, Director, Regulatory Affairs, Fougere Pharmaceuticals Inc., a Sandoz Company

**Sandra D'Agostino-Ferlisi**, Associate Director Regulatory Affairs Intelligence and Training, Apotex Inc.

**Joyce Delgaudio**, Senior Director, Regulatory Affairs, Preapproval Generics, Teva Pharmaceuticals

**Victoria Donnelly**, Public Affairs Specialist, Office of Communications and Project Management, ORA, FDA

**Madhuri Gupta**, Manager, Global Regulatory Affairs, Apotex Inc.

**Ravi Harapanhalli, PhD**, Senior Vice President, Global Regulatory Affairs, Amneal Pharmaceuticals

**Cheryl Hawkins**, Management Analyst, Division of User Fee Management and Budget Formulation, OM, FDA

**Richard Holl, PhD**, Director, Development Operations, Lupin Research Inc.

**LCDR Evelyn Hong, PharmD**, Program Manager, Division of User Fee Management and Budget Formulation, OM, FDA

**Sudhir Kaushal, MPharm**, Director, Regulatory Affairs, Lupin Pharmaceutical Inc.

**John Kennedy**, Manager, Regulatory Affairs, Sandoz Inc.

**Maria Kim, DPT**, Project Manager, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

**Anita Kumar**, Director R&D, Amneal Pharmaceuticals

**Pavan Kumar, PhD**, Director, Regulatory Affairs, Amneal Pharmaceuticals

**Gargi Lakhwani, MS, RAC** Regulatory Affairs Associate, Amneal Pharmaceuticals

**Michelle Lee-Bourner**, Head Global Respiratory Regulatory, Regulatory Affairs, Mylan Inc.

**Theresa Leh**, Associate Director, Regulatory Affairs, Fougere Pharmaceuticals Inc., a Sandoz Company

**Brian McCormick**, General Counsel, Regulatory and Lifecycle, Teva Pharmaceuticals

**Anna McDermott-Vitak**, Senior Vice President, Corporate Development and Administration, AAM

**Scott McGuinness, Bsc, MSc, QARA** Regulatory Affairs Association III, Sandoz Inc.

**Ann Marie Montemurro**, Director, Division of Pharmaceutical Quality Programs, Office of Pharmaceutical Quality Operations, ORA, FDA

**Dattatraya (Datta) Nagargoje**, General Manager, Regulatory Affairs, Mylan Inc.

**Milind Narvekar, MSc, PhD**, Head, Regulatory Affairs, Apotex Research Pvt. Ltd

**Martina O'Sullivan**, Head of Global Regulatory Affairs (Injectables), Mylan Inc.

**Jill Pastore**, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

**Alpesh Patel**, Vice President, Global Regulatory Affairs, Amneal Pharmaceuticals

**Krushangi Patel, MS**, Regulatory Affairs Specialist, Amneal Pharmaceuticals

**Priyanka Pawar, PhD**, Associate Vice President, Regulatory Affairs, Amneal Pharmaceuticals

**Gisa Perez, MBA**, Generics Branch Chief, Division of User Fee Management and Budget Formulation, OM, FDA

**LCDR Hanah Pham, PharmD**, Facilities Team Lead, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

**Jonathan Resnick**, Project Management Officer, DDMSS, FDA

**Jyoti Sachdeva, PhD**, Senior Director, Regulatory Affairs, Mylan Inc.

**Jia Jian Shen**, Project Management Officer, DDMSS, FDA

**Jewel Smith**, Director, Operations, AAM

**Olivia Souweine**, Med, Management Analyst, Applications Team, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

**Adam Steinberg, PharmD**, Project Manager, US Regulatory Affairs, Apotex Corp.

**Kandasamy Subburaj, PhD**, Director, Regulatory Affairs, Lupin Pharmaceuticals, Inc.

**Meghal Vakil**, Regulatory Project Manager, Apotex Corp.

**Janet Vaughn**, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

**Katherine (Katie) Wilson**, Director, Global Regulatory Affairs Policy, Mylan Inc.

**CDR Leo Zadecky, RPh**, Senior Program Management Officer, Drug Storage Staff, FDA

6:00 p.m. – 6:30 p.m.

**Networking Reception** – Grand Ballroom Foyer

6:30 p.m. – 9:00 p.m.

**AAM Lip Sync Battle Dinner and Entertainment** – Salon D-E

**Wednesday, November 8, 2017**

**2017 AAM Fall Technical Conference - Day 3**

7:30 a.m. – 8:30 a.m.

**Networking Breakfast** – Salon A-C

8:30 a.m. – 9:30 a.m.

**Anatomy of an Expedited/Priority Review**

Moderator: **Robert "Bob" Pollock, RPh, MS**

Senior Advisor, Outside Director to the Board  
Lachman Consultant Services, Inc.

**Kurt Karst, JD**

Director, Hyman, Phelps & McNamara, P.C.

**Scott Tomsky, MS, BS**

Vice President, Regulatory Affairs, Generics North America  
Teva Pharmaceuticals

9:30 a.m. – 11:00 a.m.

**Data Integrity Issues in Today's Complex and Global  
Manufacturing Supply Chain**

Moderator: **Derek Glover**

Head of Global Quality Systems and Compliance  
Mylan Pharmaceuticals Inc.

**Derek Smith, PhD**

Branch Chief (Acting), Division of Inspectional Assessment  
Office of Process and Facility (OPF), OPQ, FDA

**Frances Zipp**

President & CEO, Lachman Consultant Services, Inc.

**LCDR Mahesh Ramanadham, PharmD, MBA** (panelist)

Director (Acting), Division of Inspectional Assessment, OPF, OPQ FDA

11:00 a.m. – 11:30 a.m.

**Networking Refreshment Break** – Grand Ballroom Foyer

11:30 a.m. – 12:00 p.m.

**Update – Implementation of GDUFA II User Fees**

Moderator: **Candis Edwards**

Senior Vice President, Regulatory Affairs, Amneal Pharmaceuticals

**Donal Parks, MBA, MPM**

Director, Division of User Fee Management and Budget Formulation Office  
of Management, FDA

12:00 p.m. – 1:30 p.m.

**Fall Technical Conference Luncheon** – Salon A-C / White Oak

1:30 p.m. – 2:30 p.m.

**Fall Technical Conference Breakout Sessions**

<p><b>GDUFA II Implementation – Industry Negotiators Perspective on the First Month</b></p> <p>Salon D-E</p>	<p><b>Highlights from FDA-USP Workshop on Excipients</b></p> <p>Salon H</p>	<p><b>The Path to Bioequivalence – Great Progress, Great Opportunities</b></p> <p>Salon G</p>
<p><u>Moderator:</u>  <b>Marcy Macdonald, RAC</b>  Vice President, Regulatory Affairs, Impax Laboratories</p> <p><b>Kiran Krishnan, PhD</b>  Senior Vice President, Global Regulatory Affairs, Apotex Corp.</p> <p><b>Lisa Parks, RPh</b>  Vice President, Sciences &amp; Regulatory Affairs, AAM</p> <p><b>Molly Rapp</b>  Vice President, Regulatory Affairs US Innovation and Development, Generics and Standard Solutions Fresenius Kabi USA, LLC</p> <p><b>Scott Tomsky, MS, BS</b>  Vice President, Regulatory Affairs, Generics North America Teva Pharmaceuticals</p>	<p><u>Moderator:</u>  <b>Ravi Harapanhalli, PhD</b>  Senior Vice President, Global Regulatory Affairs Amneal Pharmaceuticals</p> <p><b>John Giannone</b>  Senior Director, Excipients, Strategic Marketing and Program Operations USP</p> <p><b>Catherine Sheehan, MS</b>  Senior Director Science-Excipients, USP</p>	<p><u>Moderator:</u>  <b>Dominique Kendrick, RPh, MBA, RAC</b>  President, EverestGreen Partners, Inc.</p> <p><b>Charles DiLiberti</b>  President Montclair Bioequivalence Services, LLC</p> <p><b>Keith Gallicano, PhD</b> (panelist)  Chief Scientific Officer, Novum Pharmaceutical Research Services</p>

2:30 p.m. – 3:00 p.m.

**Networking Refreshment Break** – Grand Ballroom Foyer

3:00 p.m. – 4:00 p.m.

**Fall Technical Conference Breakout Sessions**

<p><b>Complexity of Retention Samples Selection in Non-Traditional Bioequivalence Studies</b></p> <p>Salon D-E</p>	<p><b>Drug Product Quality and the Impact of Extractables and Leachables</b></p> <p>Salon H</p>	<p><b>Improving Timeliness of ANDA Approval – A CDMO Perspective</b></p> <p>Salon G</p>	<p><b>Drug Product Market Supply – Compliance and Challenges</b></p> <p>Salon F</p>
<p><u>Moderator:</u>  <b>Siva Vaithiyalingam, PhD</b>  Vice President, Regulatory Affairs North America, Cipla LTD</p> <p><b>Nageshwar Thudi, PhD</b>  Director, Clinical Research and Development, Teva Pharmaceuticals</p>	<p><u>Moderator:</u>  <b>Dominique Kendrick, RPh, MBA, RAC</b>  President, EverestGreen Partners, Inc.</p> <p><b>Diane Paskiet, MS</b>  Senior Director, Global Scientific Affairs, West Pharmaceuticals</p> <p><b>Andrea Redd, BS</b>  Director, US Regulatory Affairs Fresenius Kabi USA, LLC</p>	<p><u>Moderator:</u>  <b>Mark Hendrickson</b>  Senior Director, Sciences &amp; Regulatory Affairs, AAM</p> <p><b>L. Lee Karras</b>  Chief Executive Officer Halo Pharmaceutical</p> <p><b>Karunakar Sukuru, RPh, PhD</b>  Vice President, Product Development (US&amp;EU), Softgel Technologies, Catalent Pharma Solutions</p>	<p><u>Moderator:</u>  <b>Candis Edwards</b>  Senior Vice President, Regulatory Affairs, Amneal Pharmaceuticals</p> <p><b>Lara Hansen</b>  Associate Director, Regulatory Affairs, Sandoz Inc.</p>

4:00 p.m.

**Conference Concludes**